COMMUNIQUÉS West-GlobeNewswire

ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA
27/06/2017
GHENT, Belgium, 27 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Merck & Co., Inc., Kenilworth, New Jersey, USA, known as MSD outside the United States and Canada, has started an IND- [...]
Ossur Hf : Transactions in relation to share buyback program
26/06/2017
Announcement from Össur hf. No. 46/2017 Reykjavík, 26 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Sanofi : Disclosure of trading in own shares
26/06/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
26/06/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Scientific breakthrough on objective diagnosis of PTSD
26/06/2017
Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD Medibio has exclusive worldwide [...]
Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients
26/06/2017
DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on [...]
Novo Nordisk A/S - Share repurchase programme
26/06/2017
Bagsværd, Denmark, 26 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units
26/06/2017
Reference is made to the stock exchange notice of 14 June 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee [...]
Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL
26/06/2017
PRESS RELEASE Estelle® Phase IIb results on well-being and BODY weight published in LEADING peer-reviewed journal European Journal Of Contraception and Reproductive Health Care publishes article on Phase IIb results of [...]
ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS
26/06/2017
To assess the safety and tolerability of single and multiple doses of caplacizumab in Japanese healthy volunteers To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of caplacizumab in Japanese and [...]
INNATE PHARMA : Results of Annual General Meeting and changes to Innate Pharma's governance and management team
26/06/2017
Results of Annual General Meeting and changes to Innate Pharma's governance and management team · All proposed resolutions were voted according to management's recommendations; · Bpifrance Participations, represented by [...]
INNATE PHARMA : Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société
26/06/2017
Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société Toutes les résolutions proposées ont fait l'objet d'un vote conforme aux recommandations du Directoire ; Bpifrance [...]
Bone Therapeutics SA: Receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform
26/06/2017
Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform European IP protection for company's allogeneic technology expected until 2029 Gosselies, Belgium, [...]
Bone Therapeutics SA: Reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique
26/06/2017
Bone Therapeutics reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique Protection de la Propriété Intellectuelle liée à [...]
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23/06/2017
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved event-free survival in [...]
Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
23/06/2017
Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017 - Dr. Nils Clausnitzer elected as member of the Supervisory Board Amsterdam, the Netherlands, and Holzgerlingen, Germany, June 23, 2017 -- [...]
Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial
23/06/2017
Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for [...]
SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA
23/06/2017
More than 35 presentations and sessions showcase Shire's gene therapy pipeline and leading factor portfolio Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused [...]
Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial
23/06/2017
Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU [...]

Pages